Center for international blood and marrow transplant research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort

Mukta Arora; Michael T. Hemmer; Kwang Woo Ahn; John P. Klein; Corey S. Cutler; Alvaro Urbano-Ispizua; Daniel R. Couriel; Amin M. Alousi; Robert Peter Gale; Yoshihiro Inamoto; Daniel J. Weisdorf; Peigang Li; Joseph H. Antin; Brian J. Bolwell; Michael Boyiadzis; Jean Yves Cahn; Mitchell S. Cairo; Luis M. Isola; David A. Jacobsohn; Madan Jagasia; Thomas R. Klumpp; Effie W. Petersdorf; Stella Santarone; Harry C. Schouten; John R. Wingard; Stephen R. Spellman; Steven Z. Pavletic; Stephanie J. Lee; Mary M. Horowitz; Mary E.D. Flowers

doi:10.1016/j.bbmt.2014.10.022

Center for international blood and marrow transplant research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort

Mukta Arora, Michael T. Hemmer, Kwang Woo Ahn, John P. Klein, Corey S. Cutler, Alvaro Urbano-Ispizua, Daniel R. Couriel, Amin M. Alousi, Robert Peter Gale, Yoshihiro Inamoto, Daniel J. Weisdorf, Peigang Li, Joseph H. Antin, Brian J. Bolwell, Michael Boyiadzis, Jean Yves Cahn, Mitchell S. Cairo, Luis M. Isola, David A. Jacobsohn, Madan JagasiaThomas R. Klumpp, Effie W. Petersdorf, Stella Santarone, Harry C. Schouten, John R. Wingard, Stephen R. Spellman, Steven Z. Pavletic, Stephanie J. Lee, Mary M. Horowitz, Mary E.D. Flowers

Stem Cell Transplantation

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P < .01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all. P< .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials.

Original language	English (US)
Pages (from-to)	640-645
Number of pages	6
Journal	Biology of Blood and Marrow Transplantation
Volume	21
Issue number	4
DOIs	https://doi.org/10.1016/j.bbmt.2014.10.022
State	Published - Apr 1 2015

Keywords

Chronic graft-versus-host disease (CGVHD)
Nonrelapse mortality
Risk score

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2014.10.022

Cite this

Arora, M., Hemmer, M. T., Ahn, K. W., Klein, J. P., Cutler, C. S., Urbano-Ispizua, A., Couriel, D. R., Alousi, A. M., Gale, R. P., Inamoto, Y., Weisdorf, D. J., Li, P., Antin, J. H., Bolwell, B. J., Boyiadzis, M., Cahn, J. Y., Cairo, M. S., Isola, L. M., Jacobsohn, D. A., ... Flowers, M. E. D. (2015). Center for international blood and marrow transplant research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biology of Blood and Marrow Transplantation, 21(4), 640-645. https://doi.org/10.1016/j.bbmt.2014.10.022

Center for international blood and marrow transplant research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. / Arora, Mukta; Hemmer, Michael T.; Ahn, Kwang Woo et al.
In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 4, 01.04.2015, p. 640-645.

Research output: Contribution to journal › Article › peer-review

Arora, M, Hemmer, MT, Ahn, KW, Klein, JP, Cutler, CS, Urbano-Ispizua, A, Couriel, DR, Alousi, AM, Gale, RP, Inamoto, Y, Weisdorf, DJ, Li, P, Antin, JH, Bolwell, BJ, Boyiadzis, M, Cahn, JY, Cairo, MS, Isola, LM, Jacobsohn, DA, Jagasia, M, Klumpp, TR, Petersdorf, EW, Santarone, S, Schouten, HC, Wingard, JR, Spellman, SR, Pavletic, SZ, Lee, SJ, Horowitz, MM & Flowers, MED 2015, 'Center for international blood and marrow transplant research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort', Biology of Blood and Marrow Transplantation, vol. 21, no. 4, pp. 640-645. https://doi.org/10.1016/j.bbmt.2014.10.022

@article{92bbf9fe307e4a99a1298d6ebdb4ce1f,

title = "Center for international blood and marrow transplant research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort",

abstract = "We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P < .01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all. P< .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials.",

keywords = "Chronic graft-versus-host disease (CGVHD), Nonrelapse mortality, Risk score",

author = "Mukta Arora and Hemmer, {Michael T.} and Ahn, {Kwang Woo} and Klein, {John P.} and Cutler, {Corey S.} and Alvaro Urbano-Ispizua and Couriel, {Daniel R.} and Alousi, {Amin M.} and Gale, {Robert Peter} and Yoshihiro Inamoto and Weisdorf, {Daniel J.} and Peigang Li and Antin, {Joseph H.} and Bolwell, {Brian J.} and Michael Boyiadzis and Cahn, {Jean Yves} and Cairo, {Mitchell S.} and Isola, {Luis M.} and Jacobsohn, {David A.} and Madan Jagasia and Klumpp, {Thomas R.} and Petersdorf, {Effie W.} and Stella Santarone and Schouten, {Harry C.} and Wingard, {John R.} and Spellman, {Stephen R.} and Pavletic, {Steven Z.} and Lee, {Stephanie J.} and Horowitz, {Mary M.} and Flowers, {Mary E.D.}",

note = "Publisher Copyright: {\textcopyright} 2015 American Society for Blood and Marrow Transplantation.",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.bbmt.2014.10.022",

language = "English (US)",

volume = "21",

pages = "640--645",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Center for international blood and marrow transplant research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort

AU - Arora, Mukta

AU - Hemmer, Michael T.

AU - Ahn, Kwang Woo

AU - Klein, John P.

AU - Cutler, Corey S.

AU - Urbano-Ispizua, Alvaro

AU - Couriel, Daniel R.

AU - Alousi, Amin M.

AU - Gale, Robert Peter

AU - Inamoto, Yoshihiro

AU - Weisdorf, Daniel J.

AU - Li, Peigang

AU - Antin, Joseph H.

AU - Bolwell, Brian J.

AU - Boyiadzis, Michael

AU - Cahn, Jean Yves

AU - Cairo, Mitchell S.

AU - Isola, Luis M.

AU - Jacobsohn, David A.

AU - Jagasia, Madan

AU - Klumpp, Thomas R.

AU - Petersdorf, Effie W.

AU - Santarone, Stella

AU - Schouten, Harry C.

AU - Wingard, John R.

AU - Spellman, Stephen R.

AU - Pavletic, Steven Z.

AU - Lee, Stephanie J.

AU - Horowitz, Mary M.

AU - Flowers, Mary E.D.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P < .01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all. P< .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials.

AB - We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P < .01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all. P< .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials.

KW - Chronic graft-versus-host disease (CGVHD)

KW - Nonrelapse mortality

KW - Risk score

UR - http://www.scopus.com/inward/record.url?scp=84924296139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924296139&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.10.022

DO - 10.1016/j.bbmt.2014.10.022

M3 - Article

C2 - 25528390

AN - SCOPUS:84924296139

SN - 1083-8791

VL - 21

SP - 640

EP - 645

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 4

ER -

Center for international blood and marrow transplant research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this